Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease

Neurology

Volumn 46, Issue 4, 1996, Pages 1062-1065

  Hutton, J T ^a   Koller, W C ^b   Ahlskog, J E ^c   Pahwa, R ^b   Hurtig, H I ^d   Stern, M B ^d   Hiner, B C ^e   Lieberman, A ^f   Pfeiffer, R F ^g   Rodnitzky, R L ^h   Waters, C H ⁱ   Muenter, M D ^j   Adler, C H ^j   Morris, J L ^a  

^a St Mary of the Plains Hospital   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d GRADUATE HOSPITAL   (United States)

^e MARSHFIELD CLINIC   (United States)

^f BARROW NEUROLOGICAL INSTITUTE   (United States)

^g UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^h UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^j MAYO CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; PERGOLIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

EID: 9244228479     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.4.1062     Document Type: Article

References (12)

1. Di Salle E, Ornati G, Briatico G. FCE 21336, a new ergoline derivative with a potent and long-acting lowering effect on prolactin secretion in rats [abstract]. J Endocrinol Invest 1982;5(suppl 1):45.
2. Ferrari C, Barbieri C, Caldara R, et al. Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J Clin Endocrinol Metab 1986; 63:941-945.
3. Rolland R, Piscitelli G, Ferrari C, et al. Single-dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double-blind, multicentre study. BMJ 1991;302: 1367-1371.
4. Fabbrini G, Mouradian MM, Juncos JL, et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part 1. Ann Neurol 1988;24:366-371.
5. Mouradian MM, Juncos JL, Fabbrini G, et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part 2. Ann Neurol 1988;24:372-378.
6. Jori MC, Franceschi M, Giusti MC, et al. Clinical experience with cabergoline, a new ergoline derivative, in the treatment of Parkinson's disease. In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH, eds. Advances in neurology, vol 53. Parkinson's disease: anatomy, pathology, and therapy. New York: Raven Press, 1990:539-543.
7. Lera G, Vaamonde J, Muruzabal J, Obeso JA. Cabergoline: a long-acting dopamine agonist in Parkinson's disease. Ann Neurol 1990;28:593-594.
8. Obeso JA, Lera G, Vaamonde J, Martinez-Lage JM. Cabergoline for the treatment of motor complications of Parkinson's disease [abstract]. Neurology 1991;41(suppl 1):172.
9. Ahlskog JE, Muenter MD, Maraganore DM, et al. Fluctuating Parkinson's disease: treatment with the long-acting dopamine agonist cabergoline. Arch Neurol 1994;51:1236-1241.
10. Hutton JT, Morris JL, Brewer MA. Controlled study of the antiparkinsonian activity and tolerability of cabergoline. Neurology 1993;43:613-616.
11. Lieberman A, Imke S, Muenter M, et al. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa. Neurology 1993;43:1981-1984.
12. Lera G, Vaamonde J, Rodriguez M, Obeso JA. Cabergoline in Parkinson's disease: long-term follow-up. Neurology 1993;43: 2587-2590.